ArticleClinical sarcoma research2017
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.
Article in Clinical sarcoma research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 78 citations in OpenAlex.
- Adoptive T-Cell Therapy in Sarcomas.Current oncology reports · 2025Review
- Large language models-enabled digital twins for precision medicine in rare gynecological tumors.NPJ digital medicine · 2025Article
- Article
- EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma.Cell death & disease · 2024Article
- Review
- Synergistic enhancement of the mouse Pramex1 and Pramel1 in repressing retinoic acid (RA) signaling during gametogenesis.Cell & bioscience · 2024Article
- Recent Advances in the Diagnosis, Pathogenesis, and Management of Myxoinflammatory Fibroblastic Sarcoma.International journal of molecular sciences · 2024Review
- Targeting PRAME for acute myeloid leukemia therapy.Frontiers in immunology · 2024Review
- Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors.Virchows Archiv : an international journal of pathology · 2023Article
- Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma.Cancers · 2023Review
- PRAME Staining in Sinonasal Mucosal Melanoma: A Single-Center Experience.Head and neck pathology · 2023Article
- Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas.International journal of molecular sciences · 2023Article
- Review
- Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives.Cancer management and research · 2023Review
- Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma.Frontiers in oncology · 2023Review
- Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates.International journal of molecular sciences · 2022Review
- Differential gene expression and network analysis in head and neck squamous cell carcinoma.Molecular and cellular biochemistry · 2022Article
- Article
- Lack of PRAME Expression in Cutaneous T-Cell Lymphomas.Dermatopathology (Basel, Switzerland) · 2021Article
- Cancer testis antigen PRAME: An anti-cancer target with immunomodulatory potential.Journal of cellular and molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors, including sarcoma, and PRAME-specific therapies are currently in development for other cancers such as melanoma.
methodsTo map the landscape of PRAME expression in sarcoma, we used publicly available data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) projects and determined which sarcoma subtypes and subsets are associated with increased PRAME expression. We also analyzed how PRAME expression correlates with survival and expression of markers related to antigen presentation and T cell function. Furthermore, tumor and normal tissue expression comparisons were performed using data from the genotype-tissue expression (GTEx) project.
resultsWe found that uterine carcinosarcoma highly overexpresses the PRAME antigen, and synovial sarcomas and multifocal leiomyosarcomas also show high expressions suggesting that PRAME may be an effective target of immunotherapies of these tumors. However, we also discovered that PRAME expression negatively correlates with genes involved in antigen presentation, and in synovial sarcoma MHC class I antigen presentation deficiencies are also present, potentially limiting the efficacy of immunotherapies of this malignancy.
conclusionsWe determined that uterine carcinosarcoma, synovial sarcoma, and leiomyosarcoma patients would potentially benefit from PRAME-specific immunotherapies. Tumor escape through loss of antigen presentation needs to be further studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.